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The variability in phenotypic presentations and the lack of consistency of genetic associations in mental
illnesses remain a major challenge in molecular psychiatry. Recently, it has become increasingly clear that
altered promoter DNA methylation could play a critical role in mediating differential regulation of genes
and in facilitating short-term adaptation in response to the environment. Here, we report the investigation
of the differential activity of membrane-bound catechol-O-methyltransferase (MB-COMT ) due to altered pro-
moter methylation and the nature of the contribution of COMT Val158Met polymorphism as risk factors for
schizophrenia and bipolar disorder by analyzing 115 post-mortem brain samples from the frontal lobe.
These studies are the first to reveal that the MB-COMT promoter DNA is frequently hypomethylated in schizo-
phrenia and bipolar disorder patients, compared with the controls (methylation rate: 26 and 29 versus 60%;
P 5 0.004 and 0.008, respectively), particularly in the left frontal lobes (methylation rate: 29 and 30 versus
81%; P 5 0.003 and 0.002, respectively). Quantitative gene-expression analyses showed a corresponding
increase in transcript levels of MB-COMT in schizophrenia and bipolar disorder patients compared with
the controls (P 5 0.02) with an accompanying inverse correlation between MB-COMT and DRD1 expression.
Furthermore, there was a tendency for the enrichment of the Val allele of the COMT Val158Met polymorphism
with MB-COMT hypomethylation in the patients. These findings suggest that MB-COMT over-expression
due to promoter hypomethylation and/or hyperactive allele of COMT may increase dopamine degradation
in the frontal lobe providing a molecular basis for the shared symptoms of schizophrenia and bipolar
disorder.
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INTRODUCTION
Despite strong evidence supporting a genetic basis for schizo-
phrenia and bipolar disorder, no specific gene with a major
effect has been identified as causing these complex and devas-
tating disorders that affect five million people in the USA and
120 million worldwide (1). Several lines of evidence indicate
that an improved understanding of the etiology of psychiatric
illnesses can only be obtained using integrative approaches
that consider multiple factors linked to these diseases, i.e.
genetic, epigenetic and/or environmental factors (1,2).
Methylation of the cytosine residues in the regulatory CpG
islands of genes (3,4) is one of the major molecular mechan-
isms for regulating differential gene expression in response
to environment. There are several DNA methyltransferases
that act interactively to mediate gene-specific methylation
patterns in response to environmental effects as well as the
physiological state of the cell (5–7). Although S-adenosyl
methionine (SAM) is the major donor of methyl groups for
DNA methylation, folic acid and vitamin B12 are required
for homocysteine metabolism to regenerate the pool of SAM
(8). Modification of the gene promoter methylation pattern
in response to a variable environment can have deleterious
effects similar to those derived from malfunctional alleles.
The ability of altered DNA methylation to produce a disease
phenotype in response to specific environmental insults
likely depends upon genetic susceptibility to a specific
disease (2). Recently, we and others (9,10) showed that
DNA hypermethylation-mediated hypo-expression of the
reelin gene (RELN ) in the frontal lobe of the brain correlated
with schizophrenia pathogenesis. These findings led us to
hypothesize that alterations in the expression patterns of
other neuronal network genes involved in the pathogenesis
of schizophrenia and bipolar disorder may be mediated by epi-
genetic modifications such as altered DNA methylation of
regulatory regions.
Catechol-O-methyltransferase (COMT ), one of the most
intensively investigated genes in psychiatric illnesses (2),
regulates the homeostatic levels of neurotransmitter dopamine
in the synapses. This gene is located in chromosome 22q11.21,
a region linked by several studies to schizophrenia and bipolar
disorder (11–14). COMT has two known isoforms:
membrane-bound COMT (MB-COMT ) and soluble COMT
(S-COMT ), each with its own promoter (15). MB-COMT is
the predominant form involved in the degradation of synaptic
dopamine in the human brain (15,16). MB-COMT exhibits a
functional polymorphism at codon 158 where an adenine
(A) substitution for guanine (G) in the gene sequence produces
a methionine (Met) substitution for valine (Val) in the COMT
protein. The Val-coding allele of the Val158Met polymorph-
ism codes for an enzyme with approximately three times
higher physiological activity (17). Several studies showed
that increased dopamine degradations arising from COMT
hyperactivity are associated with disturbances in attention,
executive cognition and working memory performance in
normal populations and schizophrenic patients (18–22) and
that these effects may even be progressive over time (21). In
contrast, the hypoactive allele (Met) of the gene is associated
with less variability in reaction time and greater stability in
performance (23).
Despite the fact that several studies reported an association
between the Val allele and the risk of schizophrenia and
bipolar disorder (16,24,25), meta-analyses of family-based
and case–control association studies were inconsistent (26–
28). Furthermore, the COMT Val158Met polymorphism is
linked to early onset major depressive disorder (29) and
suicide (30), suggesting that depressive symptoms may also
be associated with COMT functions. The variability in
genetic associations between the COMT Val158Met poly-
morphism and major psychiatric disorders suggests that, in
addition to a genetic basis for COMT activity, environmental
factors may also be involved in modulating the effects of the
risk allele. For example, besides folic acid and vitamin B12,
butyrate (31), tea polyphenols (32) and alcohol (33–35) influ-
ence genes promoter DNA methylation and may also affect
expression level and modulate the phenotypic outcome of
risk alleles. There is precedence in the field of cancer research
supporting epigenetic modulation of COMT function, as DNA
hypermethylation of the CpG-rich islands in the promoter of
MB-COMT has been correlated with hypo-expression of the
gene in some types of cancer (36). Here, our overall goal is
to analyze the combined genetic and epigenetic data in corre-
lation with the role of gene–environmental interactions in an
integrated model. In the present study, we provide evidence
for over-activity of the MB-COMT in the frontal lobe of
patients with schizophrenia and bipolar disorder due to over-
expression of the gene resulting from epigenetic promoter
DNA hypomethylation and, preliminarily to a lesser extent,
the presence of the hyperactive allele of COMT Val158Met
polymorphism.
RESULTS
The differential promoter DNA methylation patterns associ-
ated with altered gene expression are tissue-specific (3–5).
Frontal lobe is one of the most commonly observed dys-
functional regions of the brain in schizophrenia and bipolar
disorder (37,38). Recent studies indicate that epigenetic modi-
fications may be involved in the dysfunction of pre-
frontal cortex in schizophrenia (9,10,39). Furthermore,
schizophrenia-associated problems in attention, cognitive pro-
cesses and working memory have been linked to frontal lobe
dopamine deficiency (40). Because of the relative scarcity of
dopamine transporters in the frontal lobe of the brain, the turn-
over of dopamine is likely to be primarily dependent on the
catabolism of dopamine by the action of COMT in this
brain region (41). Therefore, we compared the status of pro-
moter DNA methylation and the corresponding transcript
levels of the MB-COMT in the frontal lobe of post-mortem
brains of schizophrenia and bipolar disorder patients against
the control subjects. In the same samples, the allele and geno-
type frequencies of the COMT Val158Met polymorphism
were also determined as an alternate or an additional mecha-
nism for regulating dopamine levels due to the hyperactivity
associated with the Val allele.
The DNA and RNA samples were derived from
Brodmann’s area 46 (dorso-lateral frontal cortex dissected
from post-mortem brains) obtained from the Stanley Medical
Research Institute (SMRI). In addition, the Harvard Brain
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Tissue Resource Center (HBTRC) provided 10 well-matched
samples of brain tissue from the frontal lobe (Brodmann’s
area 9 and 10) of schizophrenia patients and normal controls.
Demographics of these subjects are summarized in Table 1.
The ethnicity of most of the samples was white (96.6%),
except for two samples from blacks: one from a Hispanic
and one from a Native American. Although only the SMRI
data were used for matching samples for methylation analysis
(because of the lack of information on all the variables for the
HBTRC samples), the patterns of methylation were similar in
the two subgroups. Gene-expression analysis was performed
using total RNA obtained from the SMRI and RNA extracted
from the cortical area of the HBTRC brain samples.
There were no significant differences between the case and
control groups with respect to age (t ¼ 0.86, P ¼ 0.39), post-
mortem interval (t ¼20.59, P ¼ 0.55) and brain laterality
(x2 ¼ 0.06, P ¼ 0.81). Further details of the SMRI brain
samples are provided at: http://www.stanleyresearch.org/
programs/brain_collection.asp. Although there was a trend
for greater brain pH in controls compared with patients
(mean ¼ 6.6 versus 6.45, two-sample median test
Z ¼ 21.79, P ¼ 0.07), there was no effect of pH on any of
the variables (data not shown).
MB-COMT promoter methylation status of
schizophrenia and bipolar disorder patients
The methylation status of the promoter region of MB-COMT
was analyzed using methylation-specific PCR (MSP), and
representative examples are shown in Figure 1. At least two
MSP trials were carried out for each sample. Although there
was 90% consistency between two trials (the same unmethy-
lated or methylated signals in both MSP trials), a third trial
was also undertaken to define the predominant methylation
status of any ambiguous samples. In addition, bisulfite sequen-
cing (as described under Materials and Methods) was under-
taken for further clarification and confirmation. A summary
of the analyses of 35 schizophrenia patients, 35 bipolar dis-
order patients and 35 controls is shown in Table 2. In
general, it appeared that MB-COMT promoter was predomi-
nantly unmethylated in the frontal lobe of human post-mortem
brain tissue from both patients and controls. However, careful
examination of these brain samples revealed a significantly
higher frequency of methylation in control subjects (60%),
compared with either schizophrenia (26%; x2 ¼ 7.01;
P ¼ 0.004) or bipolar disorder patients (29%; x2 ¼ 7.89;
P ¼ 0.008) (Table 2). Although the frequency of methylation
in the left brain of the controls was significantly higher than
in the right brain (81 versus 42% methylated, respectively),
this difference was less pronounced in schizophrenia (29
versus 22% methylated) and bipolar disorder patients (30
versus 27% methylated) (Fig. 2). These results suggested
that the group differences in total methylation derived primar-
ily from differences inherent to the left brain between controls
and patients with schizophrenia (P ¼ 0.003) or bipolar dis-
order (P ¼ 0.002). As shown in Figure 1, a representative
example for the left brain of the control subjects (Fig. 1B, M)
indicates that the degree of CpG methylation was
relatively high in the promoter region corresponding to base
pairs 2150 to þ100 relative to the start point of the coding
region, as determined by bisulfite sequencing and detailed in
the Materials and Methods section. On the contrary, in schizo-
phrenia and bipolar disorder patients, the target cytosines of the
promoter region were hypomethylated and these changes were
found to extend even into the coding region (Fig. 1B, U).
These differences were not attributable to the effects of age
or gender (Table 3).
MB-COMT promoter methylation and alcoholism
The history and degree of life-time alcohol consumption for all of
the samples (until death) were provided by the SMRI. As recent
studies reported an association between alcoholism and promoter
DNA hypermethylation of several genes (33–35), the relation-
ship between alcohol abuse and the frequency of MB-COMT
methylation was examined. Among schizophrenia patients,
MB-COMT promotermethylationwas remarkablymore frequent
in current heavy (4/9) andmoderate (2/3) alcohol users (total 6/12
methylated ¼ 50%) than patients with no history of alcohol use
(1/9) or social drinking (1/7) (total 2/16 methylated ¼ 12.5%,
P ¼ 0.04, Fisher’s exact test). Such a pattern of alcohol abuse
was rare in controls (i.e. among the 35 control cases examined,
there were only two current-moderate abusers with an unmethy-
lated and two previous-heavy abusers with a methylated
MB-COMT promoter).
Overall, only nine out of 35 schizophrenic patients and 10 out
of 35 bipolar patients of the SMRI samples exhibited
MB-COMT promoter methylation. Interestingly, most of these
schizophrenic patients were moderate/heavy alcohol abusers
at the time of their death (6/9, 66%). Similarly, 30% of these
bipolar patients were either previously or at the time of their
death heavy alcohol abuser. Thus, overall, our data suggest
that a portion of the observed methylation could be due to
alcohol abuse and hence the actual MB-COMT methylation
rate may be even lower than what has been observed in schizo-
phrenia and bipolar patients. Despite the fact that these prelimi-
nary results may be informative, the data should be interpreted
cautiously because of our small sample size.
MB-COMT promoter methylation and drug use
We also examined the link between antipsychotic and mood
stabilizer drugs andMB-COMT promoter methylation by com-
paring the frequency of methylation in bipolar disorder
patients who were either treated or untreated with such drugs.
In the bipolar disorder samples from the SMRI, 12 patients had
used antipsychotic drugs at the time of death, whereas 16 patients
Table 1. Sample characteristics
Source Diagnosis Number of
cases
Sex M/F Age mean
(SD)
Laterality
L/R
SMRI Schizophrenia 35 26/9 42.5 (8.47) 17/18
SMRI Bipolar disorder 35 18/17 45.2 (10.54) 20/15
SMRI Control 35 26/9 44.2 (7.63) 16/19
HBTRC Schizophrenia 5 5/0 46.0 (2.74) 3/2
HBTRC Control 5 5/0 45.4 (2.61) 3/2
M, male; F, female; L, left; R, right.
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did not. The frequency ofMB-COMT promoter methylation was
the same in these two subgroups (no antipsychotic drugs: 37%
methylated versus antipsychotic drugs: 33% methylated;
x2 ¼ 0.05; P ¼ 0.82). Among the bipolar disorder patients, 20
used either antipsychotic or mood stabilizer drugs at the time of
death, whereas eight had used neither class of drugs (we did
not have drug use information for seven of the patients). Only
three patients with schizophrenia were drug-free at the time of
death. Altogether, the frequency ofMB-COMT promotermethyl-
ation was not significantly different in these two sub-groups as
well (neither drug: 45% methylated versus either drug: 30%
methylated, P ¼ 0.4). Note that half of the bipolar patients who
used neither drug and exhibited methylation of MB-COMT
promoter were heavy alcohol abusers at the time of death. By
excluding them from this analysis, 33% of non-drug users
show methylation of MB-COMT promoter. Interestingly, the
use of histone deacetylase/DNA methylation-inhibitor valproate
also did not specifically alter methylation status (29% exhibited
methylation out of 17 valproate users). These results support
the idea that antipsychotic or mood-stabilizing drugs were not
responsible for the observed methylation differences. Further-
more, our analyses indicate that smoking, brain pH, post-mortem
interval and age of onset did not affect the frequency of
MB-COMT methylation (data not shown).
Expression analysis of MB-COMT
It has been well established in the literature that hypermethy-
lation of the promoter DNA generally correlates with silencing
of gene expression (3,5). We treated a cancer cell line, H441,
which exhibited partial MB-COMT promoter DNA methyl-
ation, with 5-azacytidine (a demethylating agent) as described
Figure 1. Representative examples of the MSP and sequence analyses of MB-COMT promoter. Brain samples from schizophrenia and bipolar disorder patients
and control subjects were analyzed using MSP as outlined under Materials and Methods. (A) MSP: lanes U and M indicate the presence of unmethylated and
methylated templates, respectively. Placental DNA (PD) and in vitro methylated DNA (ID) served as negative and positive controls, respectively. A no-template
sample (H2O) was used to detect DNA contamination in the PCR reactions. Samples 1–3 indicate the presence of a methylated promoter DNA and samples 4–7
represent an unmethylated promoter. (B) Bisulfite sequencing of the MB-COMT promoter of an un-methylated template (sample 4) correlates with conversion of
cytosine (C) to thymine (T) in the DNA sequence traces in the promoter region corresponding to CpGs (U). However, the samples exhibiting methylation
(sample 1) contained sequence traces for Cs in addition to Ts at several CpGs (which include two SP1 binding sites), indicating that the template is a
mixture of unmethylated and methylated DNA (M). The color codes for the nucleotides are as follows: red, thymine; green, adenine; black, guanine and
blue, cytosine. The original DNA sequence is indicated at the top of the trace; red Cs are within CpG sequences and are targets for methylation.
Table 2. Frequency of MB-COMT promoter methylation in the SMRI samples as determined by MSP
Methylated/total (%)
Frontal lobe hemisphere Left Right Total
Schizophrenia 5/17 (29) 4/18 (22) 9/35 (26)
Bipolar 6/20 (30) 4/15 (27) 10/35 (29)
Control 13/16 (81) 8/19 (42) 21/35 (60)
Comparison OR (95% CI); P OR (95% CI); P OR (95% CI); P
Control versus schizophrenia 0.10 (0.01–0.61); 0.003 0.39 (0.10–1.59); 0.197 0.23 (0.07–0.71); 0.004
Control versus bipolar disorder 0.10 (0.02–0.46); 0.002 0.50, (0.12–2.07); 0.350 0.27 (0.09–0.80); 0.008
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elsewhere (42). We found that there was a prominent induc-
tion of MB-COMT expression (data not shown) confirming a
similar observation made in an independent study (36). There-
fore, we examined the relationship between MB-COMT pro-
moter DNA methylation status and gene expression in the
HBTRC and SMRI samples.
The expression analysis of MB-COMT at the transcript level
was undertaken for the frontal cortical area of the brain tissues
provided by the HBTRC using semi-quantitative reverse trans-
criptase PCR (RT-PCR) and was subsequently confirmed by
quantitative real-time PCR (qRT-PCR). To minimize the
effects of confounding variables, we dissected the brain
cortex of the HBTRC samples who were male with a mean
age of 46 and a narrow range of age (SD ¼ 2.7). Pure gray
matter was excised and DNA and RNA were extracted from
the same sections using TRIzol. Semi-quantitative RT–PCR
analysis of these samples showed a distinct pattern of over-
expression of MB-COMT in schizophrenia patients, compared
with control subjects (Fig. 3A). In order to further clarify and
confirm the differences in MB-COMT expression in patients
and controls, we re-evaluated these samples by qRT-PCR
(Table 4). Overall, we found that there was 2.7 times higher
expression of MB-COMT in schizophrenia patients than in
controls using the samples from the HBTRC (Table 4).
Furthermore, qRT-PCR analysis of the SMRI samples also
showed that the transcript level was significantly
(t ¼ 22.37, P ¼ 0.02) higher in patients with schizophrenia
and bipolar disorder compared with control subjects
(Fig. 3B). However, the magnitude of this difference was
less than what was observed in the HBTRC samples. One pos-
sibility for this difference may be derived from the nature of
the tissues used for the extraction of RNA. We used the
same brain section from the gray matter for the isolation of
both DNA and RNA for the HBTRC samples, whereas hom-
ogenized brain tissues dissected from adjacent cortical brain
regions were used to extract either DNA or RNA for the
SMRI samples, due to an established sample collection pro-
cedure of the provider. Nevertheless, as expected, both semi-
quantitative RT–PCR (Fig. 3A) and qRT-PCR data
(Fig. 3B, Table 4) were consistent in revealing an inverse cor-
relation between MB-COMT promoter methylation and
expression (Fig. 3C). Furthermore, the level of MB-COMT
expression of combined samples exhibiting unmethylated
MB-COMT promoters was 56% more than the controls that
exhibited methylation in the left brain. This was even more
prominent among 11 schizophrenic and bipolar patients who
were drug-free at the time of death. Excluding the two patients
who were severely alcoholic, the expression of MB-COMT
among these patients with an unmethylated promoter was
more than 2-fold higher than controls with a methylated pro-
moter in the left frontal lobe of the brain. These studies also
showed that the expression levels of MB-COMT with Met-
or Val-coding alleles were not drastically different (data not
shown).
Inverse correlation between MB-COMT and DRD1
expression
As aberrant MB-COMT promoter methylation and correspond-
ing differential expression patterns could influence the level of
synaptic dopamine and the expression of downstream genes,
we analyzed the expression of DRD1 at the level of transcrip-
tion in the same brain samples using qRT-PCR, as described
under Materials and Methods. In general, there was an
overall hypo-expression of DRD1 in the patients compared
with the control subjects, with a clear inverse correlation
between MB-COMT and DRD1 expression both in controls
and in patients (Fig. 4). In order to quantify the correlation
between MB-COMT and DRD1expression, we classified the
total samples, controls and patients groups into two subgroups
(low and high MB-COMT expressive) as sorted by MB-COMT
expression levels. There was a significant degree of inverse
correlation between MB-COMT and DRD1 expression in the
52 low and 52 high MB-COMT expressive groups of the
total samples (P ¼ 0.001; two-tailed t-test). The expression
of DRD1 in 17 schizophrenic and bipolar disorder patients
with high levels of MB-COMT was also significantly
reduced compared with the same group with low levels of
MB-COMT (P ¼ 0.045 and 0.025, respectively; two-tailed
t-test) (Fig. 4). A trend for such relationship in the control
subjects was also detected (P ¼ 0.058). It is also noteworthy
that the expression of DRD1, in high MB-COMT expressive
schizophrenic and bipolar disorder patients, was signi-
ficantly less than the control subjects (P ¼ 0.006 and 0.03,
respectively).
COMT Val158Met polymorphism in schizophrenia
and bipolar disorder
The hyperactive Val allele of the Val158Met polymorphism
was linked to schizophrenia and bipolar disorder (25,26).
Therefore, to determine the relative contributions of either
genetic or epigenetic alterations in the pathogenesis of
Figure 2. The effect of laterality of brain in MB-COMT promoter DNA
methylation. The frequency of methylated MB-COMT promoter in the left
and right hemispheres of the brains of patients with schizophrenia (SCZ) or
bipolar disorder (BPD) and normal controls.
Table 3. DNA methylation status as a function of gender
Methylated/total (%)
Male Female Gender (x2, P)
Total sample 27/69 (39) 13/36 (36) 0.13 (0.72)
Schizophrenia 7/26 (27) 2/9 (22) 0.11 (0.74)
Bipolar disorder 4/17 (23) 6/18 (33) 0.41 (0.52)
Control 16/26 (62.) 5/9 (56) 0.10 (0.75)
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schizophrenia and bipolar disorder, we surveyed the potential
contribution of this polymorphism in the same samples used
for the evaluation of MB-COMT promoter methylation status
(Fig. 5). Although the data should be interpreted cautiously
because of the small sample size (i.e. 115), we found that
the frequency of the Val allele was significantly low in con-
trols (37.5%) compared with the patients with schizophrenia
(55.0%, P ¼ 0.026) in the SMRI and HBTRC samples com-
bined. In addition, controls were less frequently homozygous
for the Val allele (10%) compared with the patients with
bipolar disorder (28.5%, P ¼ 0.040) (Table 5). The frequency
of Met homozygosity also exhibited a corresponding increase
in controls compared with the schizophrenics (35 versus 15%,
P ¼ 0.04), but not bipolar disorder patients. Additionally, the
overall age of onset of schizophrenia in patients homozygous
or heterozygous for the Val allele was 7 years younger
compared with the patients homozygous for Met (20.2 versus
27.4 years, t ¼ 2.60, P ¼ 0.014). Thus, the presence of the
Val allele exhibits a significant correlation (P ¼ 0.01) with an
earlier onset of schizophrenia. Furthermore, we found a corre-
lation between COMT Val homozygosity and DNA hyper-
methylation of the RELN promoter in a cAMP-response
element as determined using a previously described method
(9). All of the schizophrenics and control subjects with a Val/
Val genotype exhibited a hyper-methylated RELN promoter
(14/14), whereas it was only 50% (10/20) in Met/Met homozy-
gotes (P ¼ 0.01) and 75.5% in Val/Met heterozygotes.
Our analyses reported here provide a clear trend that needs
to be further validated in a larger population in the future
studies. Indeed, given our small sample size, the observed
association between Val allele and these mental diseases
should be considered cautiously, particularly due to the
lower frequency of the Val allele in our control subjects com-
pared with larger studies in Caucasians (e.g. 49% in reference
26 and 42% in alfred.med.yale.edu). Note that within our data
set, the data on allele frequencies are consistent with the
Hardy–Weinberg equilibrium. The observed frequencies of
COMT genotypes did not significantly deviate from those
expected under Hardy–Weinberg equilibrium for controls
[x2(1) ¼ 1.20, P ¼ 0.273], schizophrenia patients [x2(1) ¼ 1.80,
P ¼ 0.180] or bipolar disorder patients [x2(1) ¼ 0.25,
P ¼ 0.615].
As mentioned earlier, our objective in studying this poly-
morphism was to undertake an integrated approach to
examine both genetic and epigenetic factors involved in the
pathogenesis of major mental disorders. In our sample set,
Figure 3. MB-COMT expression profiles of schizophrenia and bipolar disorder and the relationship between methylation status and MB-COMT expression.
(A) Semi-quantitative RT-PCR of schizophrenia and control samples was performed as described under Materials and Methods. Control samples were
loaded in lanes 1–5 and samples from schizophrenia patients were loaded in lanes 6–10. bActin was used as an internal standard to normalize the abundance
of the RT-PCR product derived from theMB-COMT gene. (B) qRT-PCR analysis of the patients and control subjects was performed as described under Materials
and Methods. For each sample (1–35, X-axis), the relative quantitation of the MB-COMT expression compared with the mean of the controls is sorted from
minimum to maximum level (Y-axis). As indicated earlier, most of the schizophrenic (SCZ) and bipolar disorder patients (BPD) show higher levels of expression
of the MB-COMT in the frontal lobe compared with the controls. (C) MSP analysis showing levels of methylation in representative samples from (A).
Table 4. MB-COMT expression analysis of HTBRC samples by qRT-PCR
Samples 1 2 3 4 5 6 7 8 9 10
Brain laterality R R L L L L R L R L
Methylation status M M M M U U U U U M
Relative expression of MB-COMT 0.84 1.15 0.5 0.87 2.45 2.3 4.6 2.3 4.6 1.7
Relative fold change Controls ¼ 1.16 (SD ¼ 0.76) SCZ ¼ 3.1 (SD ¼ 1.4)
Patients versus controls (t ¼22.74, P ¼ 0.026)
R, right; L, left; M, methylated; U, unmethylated.
Samples 1–5 are from controls and 6–10 from schizophrenic patients. CT value was used for relative quantitation of MB-COMT expression
(normalized to GADPH gene expression as an internal control). Fold changes was calculated as 22DDCT.
Human Molecular Genetics, 2006, Vol. 15, No. 21 3137
 at N
ERL on M
ay 16, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
differences in frequency of MB-COMT hypomethylation in the
left brain (51%) and differences in Val homozygosity between
all cases and controls (16.5%) were found to explain 60% of
the variance in risk for either schizophrenia or bipolar disorder
(51% plus 16.5% minus overlaps). Interestingly, among 14
schizophrenic and bipolar patients of the SMRI samples
with Met homozygosity, the only patient who was diagnosed
as schizo-affective and one bipolar patient with severe alco-
holism had a methylated MB-COMT promoter (13%, both of
them in right hemisphere), whereas nine of 13 controls with
such genotype had a methylated MB-COMT promoter (69%,
x2 ¼ 10.83, P ¼ 0.001).
The effect of COMT Val158Met polymorphism
and promoter hypomethylation on suicide
Val homozygosity and MB-COMT hypomethylation were also
examined in bipolar patients who had committed suicide.
Among 15 bipolar patients who died due to suicide, 12 had
MB-COMT promoter hypomethylation (80%), whereas two
of the three who had a methylated COMT promoter were
Val homozygous. The rate of suicide was 60% (6/10) and
33% (3/9) among Val and Met homozygotes, respectively. It
is also noteworthy that all of the Met homozygotes in the
suicidal group had a hypomethylated MB-COMT promoter.
After excluding the three patients from the non-suicidal
group who died due to drowning which may or may not
reflect a suicidal attempt, the frequency of either MB-COMT
hypomethylation or Val homozygosity was 93% (14/15) and
65% (11/17) in the suicidal and non-suicidal bipolar groups,
respectively (x2 ¼ 3.82, P ¼ 0.05). Despite no conclusive
pattern of promoter methylation or Val158Met COMT
polymorphism in the seven schizophrenic patients who
died by suicide, there were no cases exhibiting Met homo-
zygosity with a methylated MB- COMT promoter among
all suicidal patients, including schizophrenics. Interestingly,
the average level of MB-COMT expression in the suicidal
patients with Met homozygosity was 55% more than other
patients.
Figure 4. Relationship between the expression of MB-COMTand DRD1. The upper (A) and lower (B) panels represent the gene expression profiles of high
and low expressive MB-COMT groups, respectively, in total samples, control subjects, schizophrenia (SCZ) and bipolar disorder patients (BPD). As it is
shown, when MB-COMT expression is high, the expression of DRD1is low and vice versa, both in control subjects and in the patient group implying that,
in general, hyper-expression of MB-COMT is associated with hypo-expression of DRD1.
Figure 5. COMTVal158Met polymorphism in schizophrenia and bipolar dis-
order. The COMT Val158Met polymorphism analysis was performed as
described under Materials and Methods. Briefly, COMT gene-specific PCR
products encompassing the polymorphic region were cleaved by the NlaIII
restriction enzyme to an 88 bp fragment and two variable fragments 96 and
114 bp in length, which indicated the Met and Val alleles, respectively. The
first lane contains a 50 bp DNA ladder used as the marker. Representative
examples are shown for heterozygosity (lanes 2, 4, 5 and 7), Met homozygo-
sity (lanes 3 and 9) and Val homozygosity (lanes 6, 8 and 10).
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These data suggest that Met homozygosity and MB-COMT
promoter hypermethylation may be protective against schizo-
phrenia, bipolar disorder and suicide.
COMT polymorphism and promoter methylation
in cardiac disease
Because most of our control subjects died due to cardiac dis-
eases, we compared MB-COMT methylation and polymorph-
ism status in patients and controls with the same cause of
death to exclude the possibility that higher frequencies of
MB-COMT methylation and Met homozygosity may be attrib-
uted to cardiac diseases. We were particularly interested in the
fact that the frequency of the Met allele in our control samples
(62.5%) was slightly more than the average in populations of
European descent (58%) (alfred.med.yale.edu). However, our
analysis excluded this possibility as the frequency of
MB-COMT methylation was the same in 15 schizophrenic
patients who died by cardiac disease (26.5%) and in 20
bipolar patients who died by cardiac and other diseases (35%).
DISCUSSION
Our studies provide the first comprehensive molecular expla-
nation at the level of genetic and epigenetic alterations for a
direct relationship between the risk for schizophrenia and
bipolar disorder and hyperactivity of MB-COMT. MB-COMT
over-expression or hyperactivity observed in schizophrenia
and bipolar disorder (Fig 3 and Tables 4–5) could lead to a
significant increase in the rate of degradation of dopamine in
the synaptic cleft resulting in a hypodopaminergic state and
frontal lobe hypoactivity. Both schizophrenia and bipolar dis-
order patients exhibit hypofrontality, executive dysfunctions
and frontal lobe lesions with associated unresponsiveness
and failures to suppress inappropriate responses (38,43).
Additionally, negative/depressive symptoms and recognized
schizophrenia-associated problems in attention, hedonic
activities, cognitive processes, working memory and social
functioning have also been linked to dopamine dysfunction
in the frontal lobe of the brain (1,40).
There have been contradictory data on the differences in
expression of COMT in schizophrenia and mood disorders
in the literature. One study suggested that there is no
difference in the levels of COMT transcripts between cases
and controls (44), whereas another study reported a reduction
in expression in superficial cortical layers and a corresponding
increase in deep layers in schizophrenia (45). Although one
possibility is that the differential laminar distribution of
COMT transcripts could explain the lack of difference in the
overall expression levels noted in the first study, our examin-
ation of the PCR primers/probe sequences used for the analy-
sis of the COMT transcripts suggests that the primers/probes
used in these studies could amplify or hybridize with both
S-COMT and MB-COMT isoforms. A recent study reported
that promoter DNA methylatin of the S-COMT was not
involved in the pathogenesis of schizophrenia (46). In this
study, we evaluated the MB-COMT, which is regulated by a
distinct promoter and is the primary mediator of the
catabolism of synaptic dopamine in the human brain (15).
Recent studies indicate that a DRD1-mediated dopami-
nergic mechanism is responsible for working memory function
(47) and synaptic plasticity (48) in the prefrontal cortex. Here,
an inverse correlation between MB-COMT and DRD1
expression was observed both in the controls and in the
patients. This implies that frontal lobe dopamine deficiency
may cause under-stimulation of dopamine receptors and
hence a developmentally regulated hypo-expression of
DRD1gene. Thus, MB-COMT over-expression in schizo-
phrenic and bipolar patients may aggravate the end-effects
in the patients leading to long-term downstream defects in
the developing brain. In the promoter of several neuronal
genes [e.g. brain-derived neurotrophic factor (BDNF)], the
cAMP response elements (CREs) are regulated indirectly by
DRD1-like receptors through a cascade of events mediated
by cAMP, protein kinase-A and cAMP responsive element
modulator (CREM). Although promoter DNA de-methylation
leads to gene expression, neuronal inactivation could lead to
BDNF promoter methylation and lack of gene expression
(49). The promoter sequence of RELN, a gene hypo-expressed
in schizophrenia and bipolar disorder patients (10,50–53),
also harbors a CRE element that could be subject to regulation
by dopamine through DRD1 receptors (9). The observed
inverse correlation between MB-COMT and DRD1 expression
and the association between MB-COMT over-activity and
hyper-methylation of CRE in the RELN promoter in schizo-
phrenia imply that the modulatory effects of DRD1 on
RELN expression could be compromised by epigenetically
and/or genetically determined MB-COMT over-activity.
Considering the roles of RELN in cell signaling and synapse
formation, the resultant RELN hypo-expression should influ-
ence the brain neuronal network development and contribute
Table 5. Frequency of Val and Met alleles of the Val158Met polymorphism of COMT in schizophrenia, bipolar disorder and control subjects
Diagnosis Genotype frequency Allele frequency
Val/Val, N (%) Val/Met, N (%) Met/Met, N (%) Val, N (%) Met, N (%)
Control 4/40 (10.0) 22/40 (55.0) 14/40 (35.0) 30 (37.5) 50 (62.5)
Schizophrenia 10/40 (25.0) 24/40 (60.0) 6/40 (15.0) 44 (55.0) 36 (45.0)
OR (95% CI); P 3.00 (0.76–14.27); 0.078 1.23 (0.46–3.28); 0.651 0.33 (0.09–1.08); 0.039 2.04 (1.03–4.03); 0.026
Bipolar disorder 10/35 (28.6) 16/35 (45.7) 9/35 (25.7) 36 (51.4) 34 (48.6)
OR (95% CI); P 3.60 (1.06–12.08); 0.040 0.62 (0.23–1.68); 0.303 1.90 (0.62–5.83); 0.270 0.86 (0.45–1.64); 0.652
ORs and test statistics are for each patient group versus the control group.
Genotype comparisons are computed in relation to the sum of the other genotypes.
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to the diseases (10,50–53). However, a hypoactive Met allele
or promoter methylation and hypo-expression of MB-COMT
could lead to a higher synaptic dopamine level that could
illicit protective effects. Recent findings showed that acti-
vation of different forms of dopamine receptors in the fontal
lobe depends on the synaptic dopamine level (54). Low
levels of dopamine are associated with DRD1 activation,
whereas higher levels are associated with activations of both
DRD1 and DRD2 receptors that co-operate to provide the
basis for the functionality of working memory. Interestingly,
higher levels of synaptic dopamine delivered by DRD2 antag-
onists could also augment DRD1-mediated neuronal functions
(54). It is also noteworthy that our analysis of other
dopamine-related genes in the same samples revealed that in
control subjects, when MB-COMT promoter was hypomethy-
lated, almost always the DRD2 promoter was also hypomethy-
lated (data not shown). Thus, it appears that the synaptic
dopamine deficiency associated with MB-COMT hypomethy-
lation could result in secondary DRD2 promoter hypomethyla-
tion in order to fine tune the dopamine transmission in the
frontal lobe. On the contrary, in schizophrenic and bipolar
patients, the level of compensatory DRD2 hypomethylation
was significantly low compared with the extent observed in
the control subjects (data not shown).
The Met allele of the COMT gene is associated with greater
stability in performance in normal individuals (21), whereas
the Val allele is correlated with susceptibility for schizo-
phrenia, particularly in cannabis abusers (55). Also a recent
study indicates that children with 22q11 deletion, who are
hemizygous for COMT Met allele, have higher IQ and
achievement scores and perform better on measures of pre-
frontal cognition (e.g. Continuous Performance Task) com-
pared with those with the Val allele (56). Schizophrenic
patients homozygote for the Val also exhibit a significant
degree of reduction in brain volumes particularly on the left
side (anterior cingulate cortex, left amygdala-uncus and left
thalamus), compared with Met homozygotes (57). Hence,
the observed epigenetic MB-COMT hypomethylation/over-
expression effects may also contribute to worsening of these
brain abnormalities through reduction of RELN expression
or other mechanisms.
Despite the fact that the MB-COMT promoter region is
often hypomethylated in schizophrenia and bipolar disorder
patients, there was a predominant unilateral partial methyl-
ation in the control subjects. These observations may indicate
that differential expression of MB-COMT in the left frontal
lobe may occur in response to the effects of other neuronal
pathways and genes involved in brain laterality. Alternatively,
MB-COMT promoter methylation in controls could occur as a
physiological feedback response to environmentally mediated
MB-COMT over-expression. Accordingly, a steady-state level
of dopamine, required for specific neurons, is maintained to
ensure the consolidation of the left brain dominancy in
defined end effects. In contrast, the observed promoter hypo-
methylation in the left brain of schizophrenia and bipolar dis-
order patients is likely a consequence of a failure to adhere to
the predestined methylation pattern during a critical period
for the establishment of brain laterality or a failure of
physiological feedback modulation of the MB-COMT. This
idea may also provide a plausible explanation for the loss of
brain lateralization in schizophrenia and bipolar disorders
noted in several studies (58–61). One of the potential molecu-
lar mechanisms responsible for these defects could be loss of
imprinting, as there is some evidence for linkage to maternally
(but not paternally) transmitted alleles at the chromosome 22q
locus in mental disorders (13).
Note that a systemic pathogenic insult such as folic acid
deficiency during a critical developmental period can influ-
ence the extent of epigenetic modifications, including loss of
imprinting and/or aberrant promoter DNA methylation pat-
terns (62–64). Several lines of evidence indicate that folic
acid deficiency and polymorphism of genes related to folate
metabolism are associated with schizophrenia and mood dis-
orders (65–67) as reviewed elsewhere (68). Furthermore,
even the style of maternal care is known to alter offspring’s
genetic methylation patterns, as observed for the glucocorti-
coid receptor in the hippocampus (69).
Overall, these observations suggest that it may be possible
to trace the environmental influences on the modification of
methylation patterns of genes, which may affect susceptibility
to schizophrenia, bipolar disorder and possibly other mental
disorders. Accordingly, the concept of the roles of different
methylomes as the means of short-term/long-term adaptation
in response to the influences of the environment requires
further extensive studies to understand the molecular basis
of the major psychiatric disorders. It should be noted that
the analyses reported here were conducted using brain
samples corresponding to the left and right lobes from differ-
ent individuals rather than derived from the same persons due
to the lack of availability of the latter type of samples.
Although we expect that the overall findings reported here
should remain the same as pooling of the data derived with
samples from several individuals should cancel out inter-
individual variations, these investigations should be repeated
in the future using left and right lobe-derived brain samples
from the same individuals for further validation.
Despite the unavailability of an antibody to measure the
COMT protein and the lack of the ideal samples for research
due to practical issues, the establishment of an association
between promoter DNA hypomethylation and the
Val158Met polymorphism of MB-COMT in schizophrenia
and bipolar disorder would suggest new treatment modalities
in psychiatry targeting the specific dysfunctional genes.
Animal studies have demonstrated that COMT inhibitor
drugs prevent stress-induced anhedonic state, improve pre-
frontal cortex performance and potentate clozapine-induced
extra-cellular dopamine release (70,71). In human, these
drugs (e.g. tolcapone) were effective in treating major depress-
ive disorders (72,73). These observations along with the
results presented here argue that COMT inhibitor drugs may
be of benefit in the treatment of other major mental diseases.
It is interesting to note that other drugs with similar end effects
(e.g. amphetamine) improve prefrontal cortex functions affect-
ing working memory tasks in subjects with the Val/Val geno-
type of COMT (74). Mirtazapine, an antidepressant with
noradrenergic property, is also more effective than specific
serotonin re-uptake inhibitors in depressed patients with the
COMT Val allele (75). In schizophrenia, apomorphine, a
dopamine agonist, was also known to improve psychotic
symptoms (76). A recent meta-analysis of 700 patients from
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30 studies showed that the concurrent administration of
L-dopa with antipsychotic drugs could further improve the
symptoms of schizophrenia in half of the cases (77). While
generally, improvement of cognitive symptoms by atypical
antipsychotic drugs is related to prefrontal cortex dopamine
release (78), even atypical anti-psychotics such as olanzapine
are less effective in aiding working memory performance and
prefrontal physiology in schizophrenic patients with the
COMT Val allele (79). These findings along with the observed
efficacy of aripiprazole, a partial agonist of dopamine recep-
tors in psychotic disorders, imply that negative and cognitive
symptoms of schizophrenia as well as depressive symptoms
of bipolar and unipolar disorders could be targeted by
COMT-inhibitor drugs, particularly in patients with a hypo-
methylated MB-COMT promoter or the Val/Val genotype, as
we and others discussed elsewhere (2,80,81).
Conclusion
Promoter hypomethylation-associated over-expression of
MB-COMT in the left frontal lobe and or the presence of the
hyperactive Val allele of the Val158Met polymorphism may
play a significant role in the pathogenesis of major psychiatric
disorders. The connection established between MB-COMT
over-activity and pathogenesis in this report strongly suggests
that it is worthwhile to consider preventive strategies such as
nutrition- or drug-based modulation of COMT promoter DNA
methylation or the use of COMT-inhibitor drugs to prevent or
improve the symptoms of schizophrenia and bipolar disorder.
MATERIALS AND METHODS
DNA and RNA extraction
Total RNA and DNA were prepared from the same dissected
cortex of theHBTRCbrain samples, using TRIzol (Life Technol-
ogies, Inc., Grand Island, NY, USA) according tomanufacturer’s
instructions. The SMRI extracted the total RNA and DNA using
TRIzol and standard phenol–chloroform protocol, respectively,
from the adjacent cortical areas of the post-mortem brains.
cDNA synthesis and PCR amplification were performed using
standard protocols as previously described (42).
Bisulfite treatment
Bisulfite converts unmethylated cytosine to uracil, whereas
methylated cytosine remains unchanged (82). Then, a sub-
sequent NaOH treatment coverts uracil to thymine. Approxi-
mately 1 mg of genomic DNA was denatured by treatment
with 2 M NaOH and then treated with 10 mM hydroquinone
and 3 M sodium bisulfite (pH 5) at 508C for 16 h. The bisulfite-
treated DNA was purified using Wizard DNA purification
resin (Promega) and treated with 3 M NaOH, ethanol precipi-
tated with ammonium acetate and glycogen and re-suspended
in 20 ml of water.
MSP and bisulfite sequencing
MSP is known as one of the most sensitive screening methods
to distinguish between methylated and unmethylated DNA at
CpG sites. Although the sensitivity of direct sequencing of
the bisulfite-treated DNA or cloned DNA is 10–20%
(83,84), the sensitivity of MSP is known to be .1% (83).
This high sensitivity places the MSP as a highly favored
method for screening of the methylated CpG sites within the
CpG islands (83,85,86). Our MSP analysis of the COMT
gene was carried out using primer sets described by Sasaki
et al. (36). The two sets of primers corresponding to a
CpG-rich area located in the MB-COMT gene promoter were
used to amplify methylated and unmethylated strands in separ-
ate PCR reactions. The primer sequences used for the MSP
analysis are as follows: methylated forward (MF) primer: 50-
TATTTTGGTTATCGTCGCGC-30; methylated reverse (MR)
primer: 50-AACGAACGCAAACCGTAACG-30; unmethylated
forward (UF) primer: 50-TATTTTGGTTATTGTTGTGT-30
and unmethylated reverse (UR) primer: 50-AACAAACACAAA
CCATAACA-30.
For the MSP analysis, unmethylated (placental) DNA and in
vitro methylated DNA were used as negative and positive con-
trols, respectively, whereas a no DNA control (water) was
used to detect any PCR contaminations. Various combinations
of PCR cycles and annealing temperatures were examined to
optimize PCR conditions, so that the unmethylated and
methylated template-specific primers only generated PCR pro-
ducts that represent the unmethylated and methylated con-
ditions, respectively. The high level of sensitivity of MSP
allows the efficient high throughput examination of the DNA
methylation status of test samples.
For bisulfite sequencing, the following primers were used to
amply a 421 bp fragment. Forward primer: 50-GTAAGATT
AGATTAAGAGGT-30 (36); reverse primer: 50-CAATATT
CCACCCTAAATCTAAAA-30 and a nested primer (50-GAT
ATTTTTAC(T)GAGGATATT-30) or the reverse primer was
used as the sequencing primer.
PCR conditions
Master mixes were prepared and used in the PCR amplifica-
tions. A typical reaction of a total volume of 25 ml consisted
of 2.5 ml of 10 standard buffer, 0.4 ml of 10 mM dNTPs,
1.5 ml of DMSO, 2.5 U of platinum Taq DNA polymerase
(Invitrogen) and 25 pmol of each of methylated or unmethy-
lated specific primers. Approximately 30 ng bisulfite-modified
genomic DNA was used as template. PCR amplification was
done with an initial incubation at 948C for 2 min, followed
by 31 cycles of 948C for 30 s, 578C for 40 s, 728C for 40 s,
followed by a final extension for 10 min at 728C. Ten micro-
liters of the MSP products were run on 6% polyacrylamide gel
by electrophoresis, stained with ethidium bromide and visual-
ized under UV light.
Approach for determination of MB-COMT promoter
methylation status
There were two MSP trials for each sample. As indicated
earlier, for each MSP trial, two sets of primers were used to
amplify methylated or unmethylated strands in separate PCR
reactions. Approximately, 90% of the samples showed the
same results for both MSP trials. Samples were classified as
unmethylated if no methylation signal was detected in the
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two MSP trials. Similarly, a sample was designated as methyl-
ated when a methylated signal was also detected in both
MSP trials. Representative examples of samples exhibiting
unmethylated or methylated status were subject to bisulfite
sequencing (Fig. 1). Our results indicated that samples desig-
nated unmethylated did not exhibit traces corresponding to Cs
due to complete conversion, whereas those determined to be
methylated contained sequence traces of Cs indicating the pre-
sence of methylated Cs resistant to conversion by bisulfite
treatment (see Fig. 1B for example). When the two initial
MSP trials were not consistent (i.e. unmethylated in the first
reaction and methylated in the second reaction), or whenever
a weak methylated signal was observed, a third trial was also
undertaken to define the methylation. Additionally, bisulfite
sequencing was performed to make the final determination
of the methylation status for these ambiguous samples. As
these ‘ambiguous’ cases were distributed almost equally in
different groups (three to four in each group, 11 in total)
and excluding them from the analysis did not change the
results of our statistical analyses in general, and for the
observed findings as reported, we included them in the final
analysis. Please also note that to avoid any bias with experi-
ments, the investigators were blinded for the diagnosis of
the samples until the MSP trials were completed. After the
determination of the methylation status of the samples, the
identity of samples was declared for data analysis.
Primers for MB-COMT expression analysis using
semi-quantitative RT–PCR and qRT-PCR
The gene-specific primer pair used in the analysis of
MB-COMT expression was designed from different exons
to avoid any genomic DNA amplification and by placing
them in locations which would exclusively amplify the
MB-COMT isoform. The forward and reverse primers for the
semi-quantitative RT–PCR were 50-CTGCTTTGCTGCCG
AGCTCAGAGGAGAC-30 and 50-TTCTTGTCGCCCACG
TTCATG-30. The qRT-PCR primers that solely amplify a
110 bp fragment were 50-CTGCTTTGCTGCCGAGCTCAG
AGGAGAC-30 and 50-GCCCAGCAACACAGCTGCCAAC
AG-30.
Semi-quantitative RT–PCR of the bactin gene and real-
time PCR of the GAPDH and bactin genes were used as an
internal standard to normalize the abundance of the semi-
quantitative RT–PCR and qRT-PCR products derived from
the MB-COMT gene for the HBTRC samples. The b-actin
primer sequences for the semi-quantitative RT–PCR were
50-ACACTGTGCCCATCTACGAGG-30 and 50-AGGGGCC
GGACTCGTCATACT-30 and for the qRT-PCR were 50-C
GAGCACAGAGCCTCGCCTTTGCC-30 and 50- TGTCGAC
GACGAGCGCGGCGATAT-30. The GAPDH primers were
50-CACAAGAGGAAGAGAGAGACCCTC-30 and 50-TGAG
TGTGGCAGGGACTC C-30.
qRT-PCR analysis was done twice for the HBTRC samples,
using ABI PRISM 7700 following several test trials with 1/2,
1/10, 1/100, 1/1000 diluted and no template controls with
varying amount of primers to optimize for the best conditions.
The qRT-PCR was set up in a reaction volume of 50 ml using
components supplied in a Sybr-green PCR mix (BIO-RAD,
Hercules, CA, USA). Each reaction also contained 100 nM
each amplification primer and 2 ml of 1/10 diluted DNA.
DNA amplifications were carried out in a 96-well reaction
plate (MicroAmp, Foster City, CA, USA). Thermal cycling
was initiated with a first denaturation step of 15 min at
958C. The subsequent thermal cycling profile was 958C for
15 s and 608C for 45 s. Data obtained following 40 cycles of
amplification were analyzed using the SDS 1.9.1 software.
The qRT-PCR for the SMRI samples was carried out twice
in a 384-well plate (Applied Biosystem, Foster City, CA,
USA) in a reaction volume of 10 ml using ABI PRISM
7900HT. Gene expression was measured with good reproduci-
bility between duplicates and without the formation of primer
dimers as evidenced by the appearance of a single product
with a Tm of 828C in the dissociation curve (data not
shown). Cycle threshold (CT) value was used for relative
quantitation of MB-COMT expression. Fold changes was
calculated as 22DDCT.
Primers for DRD1 expression analysis
qRT-PCR was carried out using the same condition as
described earlier for the MB-COMT analysis using ABI
PRISM 7900HT. The primers were, forward primer: 50-CT
GCGACGAATAATGCCATAGAGA-30 and reverse primer:
50-ATTGCACTCCTTGGAGATGGAGC-30.
COMT gene Val158Met polymorphism
The COMT region was PCR amplified using a previously
described primer set to evaluate the existence of the
Val158Met polymorphism (87). The primers, 50-TCGT
GGACGCCGATTCAGG-30 and 50-ACAACGGGTCAGGCA
TGC-30, were used to amplify a 207 bp fragment after 35
cycles using the previously described conditions. The PCR
products were further analyzed by restriction digestion by tar-
geting the 177th base of the fragment with the NlaIII restric-
tion enzyme to distinguish between the Val and Met alleles
(Fig. 5).
Data analysis
Univariate, bivariate and multivariate statistical tests were
used for the analysis of the data. Parametric tests were used
wherever possible. Large sample approximations (e.g. x2)
were used wherever possible; otherwise, for small samples,
exact tests were used (e.g. Fisher’s exact test). Differences
between cases (either schizophrenic or bipolar) and controls
were examined. All statistical analyses were conducted
using SAS software version 8.2. Note that the data from
SMRI and HBTRC samples were pooled only for the poly-
morphism analysis.
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